BACKGROUND: Disseminated fibrosarcoma still represents a therapeutic dilemma because of lack of effective cytostatics. Therefore we tested tumor necrosis factor related apoptosis-inducing ligand (TRAIL) and taurolidine, in combination with established and new chemotherapeutic agents on human fibrosarcoma (HT1080). MATERIALS AND METHODS: Human fibrosarcoma cells (HT1080) were incubated with doxorubicin, mafosfamide and trabectedin both alone and in combination with taurolidine and TRAIL. Vital, apoptotic and necrotic cells were quantified using flow cytometric analysis. Cell proliferation was analysed using a bromodeoxyuridine (BrdU) ELISA assay. RESULTS: Single application of doxorubicin and trabectedin induced apoptotic cell death and significantly reduced the proliferation of HT1080 cells. In combination treatment, the addition of taurolidine and TRAIL resulted in a stronger reduction in the degree of cell viability when compared to single treatment. Trabectedin and taurolidine displayed a greater potential for inhibiting proliferation than did doxorubicin alone. CONCLUSION: When combined with TRAIL and taurolidine, treatment with doxorubicin and trabectedin demonstrated stronger apoptosis-inducing and antiproliferative effects.
BACKGROUND: Disseminated fibrosarcoma still represents a therapeutic dilemma because of lack of effective cytostatics. Therefore we tested tumor necrosis factor related apoptosis-inducing ligand (TRAIL) and taurolidine, in combination with established and new chemotherapeutic agents on humanfibrosarcoma (HT1080). MATERIALS AND METHODS:Humanfibrosarcoma cells (HT1080) were incubated with doxorubicin, mafosfamide and trabectedin both alone and in combination with taurolidine and TRAIL. Vital, apoptotic and necrotic cells were quantified using flow cytometric analysis. Cell proliferation was analysed using a bromodeoxyuridine (BrdU) ELISA assay. RESULTS: Single application of doxorubicin and trabectedin induced apoptotic cell death and significantly reduced the proliferation of HT1080 cells. In combination treatment, the addition of taurolidine and TRAIL resulted in a stronger reduction in the degree of cell viability when compared to single treatment. Trabectedin and taurolidine displayed a greater potential for inhibiting proliferation than did doxorubicin alone. CONCLUSION: When combined with TRAIL and taurolidine, treatment with doxorubicin and trabectedin demonstrated stronger apoptosis-inducing and antiproliferative effects.
Authors: Marina Yu Skorkina; Elena A Shamray; Victoria A Salo; Anatoly S Buchelnikov; Maxim P Evstigneev Journal: J Bioenerg Biomembr Date: 2017-12-19 Impact factor: 2.945
Authors: Kamran Harati; Adrien Daigeler; Tobias Hirsch; Frank Jacobsen; Björn Behr; Christoph Wallner; Marcus Lehnhardt; Mustafa Becerikli Journal: Int J Mol Med Date: 2016-04-11 Impact factor: 4.101
Authors: Pablo César Ortiz-Lazareno; Alejandro Bravo-Cuellar; José Manuel Lerma-Díaz; Luis Felipe Jave-Suárez; Adriana Aguilar-Lemarroy; Jorge Ramiro Domínguez-Rodríguez; Oscar González-Ramella; Ruth De Célis; Paulina Gómez-Lomelí; Georgina Hernández-Flores Journal: Cancer Cell Int Date: 2014-02-04 Impact factor: 5.722
Authors: Man Chin Chung; Pedro Malatesta; Priscila Longhin Bosquesi; Paulo Renato Yamasaki; Jean Leandro Dos Santos; Ednir Oliveira Vizioli Journal: Pharmaceuticals (Basel) Date: 2012-10-23